Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Next Previous
Trial Profile

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab tirumotecan (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms TroFuse-027
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 06 Jul 2026 Planned End Date changed from 31 Jul 2028 to 14 Mar 2029.
  • 06 Jul 2026 Planned primary completion date changed from 30 Jun 2026 to 14 Mar 2029.
  • 03 Apr 2025 Planned End Date changed from 30 Nov 2026 to 31 Jul 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top